Topical regional neuro-affective therapy in mammals with cannabinoids

Abstract

A method of treating a disease state or condition in mammals other than humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck region and / or spine to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream or mousse. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.

Description

FIELD OF THE INVENTION[0001]The invention relates to topical regional neuro-affective therapy (“TRNA THERAPY”) with cannabinoids, such as cannabidiol (CBD) on mammals other than humans. This is accomplished via administration of effective amounts of these agents on the back of the neck region, and in certain embodiments also in proximity to the painful site or problem area.BACKGROUND OF THE INVENTION[0002]This application claims priority to U.S. Application No. 62 / 126,757, filed on Mar. 2, 2015 and U.S. Application No. 62 / 299,260, filed on Feb. 24, 2016; the disclosures of which are hereby incorporated by reference herein.[0003]The approximate 2½ pound human brain is comprised of the most complex material known to man. The neuron, the primary functional cell of the nervous system, operates on the basis of electrical impulses that result in the release of neurochemical substances (neurotransmitters) at specific receptors: dopamine, serotonin, acetylcholine, norepinephrine, gamma-amin...

AI Technical Summary

Benefits of technology

The patent is about a method for treating certain conditions in mammals, including humans, by applying a topical pharmaceutical formulation to the back of the neck region and / or along the spine. The formulation can be applied once or multiple times a day, with some conditions requiring a more frequent dosing schedule. The formulation contains a cannabinoid drug that can be absorbed through the skin. In some cases, the drug may be administered in an implantable form, which allows for controlled or sustained release of the drug at the site of administration. The technical effects of this patent include providing a non-invasive and effective treatment for certain conditions through a targeted delivery system to the back of the neck region and spine.

Problems solved by technology

While benefits for treating symptoms of diverse neurologic and psychiatric conditions have been known and practiced by ancient civilizations for thousands of years, marijuana's psychoactive effects have also led to abuse and labeling as a “gateway drug” for more addictive compounds.

However, increasing number of states have challenged this position and legalized cannabis within their territories with varying restrictions and conditions for use.